Literature DB >> 11180759

Histopathological criteria for assessment of therapeutic response in breast cancer.

M Kurosumi, F Akiyama, T Iwase, K Motomura, M Okazaki, H Tsuda.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11180759     DOI： 10.1007/bf02967471

Source DB:  PubMed          Journal:  Breast Cancer        ISSN： 1340-6868            Impact factor:   4.239


× No keyword cloud information.
  7 in total

1.  Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen.

Authors:  Yasuhiro Fujiwara; Yuichi Takatsuka; Shigeru Imoto; Hideo Inaji; Tadashi Ikeda; Futoshi Akiyama; Motoshi Tamura; Kazuya Miyoshi; Hiroji Iwata; Shoshu Mitsuyama; Shinzaburo Noguchi
Journal:  Cancer Sci       Date:  2012-01-13       Impact factor: 6.716

2.  Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial.

Authors:  Masafumi Kurosumi; Yuichi Takatsuka; Toru Watanabe; Shigeru Imoto; Hideo Inaji; Hitoshi Tsuda; Futoshi Akiyama; Goi Sakamoto; Tadashi Ikeda; Shinzaburo Noguchi
Journal:  J Cancer Res Clin Oncol       Date:  2007-12-13       Impact factor: 4.553

3.  Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation.

Authors:  Hiroyuki Takei; Takashi Yoshida; Masafumi Kurosumi; Kenichi Inoue; Hiroshi Matsumoto; Yuji Hayashi; Toru Higuchi; Sayaka Uchida; Jun Ninomiya; Kazuyuki Kubo; Hanako Oba; Shigenori Nagai; Toshio Tabei
Journal:  Int J Clin Oncol       Date:  2012-05-16       Impact factor: 3.402

4.  Changes of T2 Relaxation Time From Neoadjuvant Chemotherapy in Breast Cancer Lesions.

Authors:  Li Liu; Bo Yin; Dao Ying Geng; Yi Ping Lu; Wei Jun Peng
Journal:  Iran J Radiol       Date:  2016-01-09       Impact factor: 0.212

5.  Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period.

Authors:  Misun Choi; Yeon Hee Park; Jin Seok Ahn; Young-Hyuck Im; Seok Jin Nam; Soo Youn Cho; Eun Yoon Cho
Journal:  J Pathol Transl Med       Date:  2016-12-25

6.  TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study.

Authors:  Kenichi Inoue; Shigenori E Nagai; Tsuyoshi Saito; Takashi Sakurai; Kei Kimizuka; Hirofumi Yamada; Toru Kuroda; Satoshi Hata; Yasuo Yamazaki; Masato Kojima; Kazushige Futsuhara
Journal:  Invest New Drugs       Date:  2019-07-10       Impact factor: 3.850

7.  Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.

Authors:  Mamoru Takada; Toru Higuchi; Katsunori Tozuka; Hiroyuki Takei; Masayuki Haruta; Junko Watanabe; Fumio Kasai; Kenichi Inoue; Masafumi Kurosumi; Masaru Miyazaki; Aiko Sato-Otsubo; Seishi Ogawa; Yasuhiko Kaneko
Journal:  BMC Cancer       Date:  2013-05-16       Impact factor: 4.430
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.